With the aim of targeting plasma cell malignancy in MM that overexpress CS1, we developed a dual specific bivalent bsAb (CS1-dbBiTE) using an efficient Click chemistry method for conjugation of intact anti-CS1 (Elotuzumab) and anti-OKT3 antibodies. Here, SLAMF7 is linked to Miyoshi myopathy.